Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + cadonilimab
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of disitamab vedotin (RC48), a HER2-directed antibody-drug conjugate (ADC), and cadonilimab (AK104), a bispecific antibody targeting PD-1 and CTLA-4. Disitamab vedotin is composed of a humanized anti-HER2 antibody conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. Cadonilimab is a first-in-class bispecific antibody designed to simultaneously block the PD-1 and CTLA-4 immune checkpoints, thereby enhancing T-cell mediated anti-tumor activity. The combination is being evaluated as a second-line treatment for patients with HER2-mutant advanced or metastatic bile duct adenocarcinoma in a Phase II clinical trial led by Zhejiang Cancer Hospital. The rationale for this combination is to leverage the targeted cytotoxic effects of the ADC with the dual checkpoint inhibition of the bispecific antibody to overcome resistance and improve clinical outcomes in HER2-expressing biliary tract cancers.
- Brand names
- AidexiKaitani
- Other names
- RC48 plus AK104RC-48 plus AK104RC 48 plus AK104Disitamab Vedotin Plus Cadonilimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on disitamab vedotin + cadonilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + cadonilimab.